Jul 09,2022

Personalizing the Use of a Intermittently Scanned Continuous Glucose Monitoring (isCGM) Device in Individuals With Type 1 Diabetes: A Cost-Effectiveness Perspective in the Netherlands (FLARE-NL 9)

Intermittently scanned continuous glucose monitoring (isCGM) is a method to monitor glucose concentrations without using a finger prick. Among persons with type 1 diabetes (T1D), isCGM results in improved glycemic control, less disease burden and improved health-related quality of life (HRQoL). However, it is not clear for which subgroups of patients isCGM is cost-effective. The study aimed to provide a real-world cost-effectiveness perspective.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 20,2022

The Influence of Digital Affinity on the CGM System Choice by People With Type 1 Diabetes

The aim of the study was to investigate the influence of digital affinity on the CGM use and the choice of a particular system.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 20,2022

Use of Continuous Glucose Monitors by People Without Diabetes: An Idea Whose Time Has Come?

Continuous glucose monitor (CGM) systems were originally intended only for people with diabetes. Recently, there has been interest in monitoring glucose concentrations in a variety of other situations. As data accumulate to support the use of CGM systems in additional states unrelated to diabetes, the use of CGM systems is likely to increase accordingly.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 25,2022

Accuracy and Glycemic Efficacy of Continuous Glucose Monitors in Critically Ill COVID-19 Patients: A Retrospective Study

Continuous glucose monitoring (CGM) is approved for insulin dosing decisions in the ambulatory setting, but not currently for inpatients. CGM has the capacity to reduce patient-provider contact in inpatients with coronavirus disease 2019 (COVID-19), thus potentially reducing in hospital virus transmission. However, there are sparse data on the accuracy and efficacy of CGM to titrate insulin doses in inpatients.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 28,2022

Dexcom to update next-gen G7 software, delaying FDA clearance, launch timelines

The CEO of Dexcom (Nasdaq:DXCM) said today that the company’s regulatory path for the next-generation G7 has been slightly delayed.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 03,2022

Senseonics Announces a Positive Coverage Decision for Eversense® E3 CGM from Anthem

Senseonics Holdings, Inc. a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Anthem is providing coverage for implantable CGM, which includes the Eversense® CGM System. Anthem’s decision will add more than 45 million covered lives for the long-term implantable CGM system to help manage their diabetes.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 04,2022

Abbott, WeightWatchers partner on diabetes care

The two companies will work together to allow Abbott's FreeStyle Libre continuous glucose monitoring systems and the WeightWatchers mobile app to share information so that people living with diabetes can see their glucose data alongside WeightWatchers' diabetes-tailored program.  

COLLABORATION PARTNERSHIP

#connected device

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 12,2022

Abbott will spend $450M to up FreeStyle Libre production in Ireland

Abbott will spend €440 million ($450 million) to expand its operations in Ireland, the country’s government announced today.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 01,2022

Factory-Calibrated Continuous Glucose Monitoring System Accuracy During Exercise in Adolescents With Type 1 Diabetes Mellitus

To investigate the accuracy of the Dexcom G6 during physical activity

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 01,2022

Medtronic ADAPT study results published in The Lancet Diabetes & Endocrinology show improved glycemic control and treatment satisfaction among those using MiniMed™ 780G system, compared to insulin injections

First-of-its-kind study demonstrates individuals using the Medtronic system achieved 1.4% absolute reduction in A1c and 27.6% absolute increase in Time in Range

CLINICAL STUDY

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM